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Regulation of vascular permeability factor/vascular endothelial
growth factor (VPF/VEGF-A) expression in podocytes.
Background. Vascular permeability factor/vascular endothe-
lial growth factor (VPF/VEGF-A) is expressed constitutively in
the adult glomerular podocytes at high levels; however, the reg-
ulation of its production is unclear. Recent data from podocyte-
specific knockout mice suggest that VPF/VEGF-A is critical
for the proper maintenance of glomerular filtration barrier and
the glomerular endothelial fenestrae. We hypothesized that
the glomerular basement membrane (GBM) matrix–podocyte
interaction may play a role in the constitutive expression of
VPF/VEGF-A in the adult glomerulus.
Methods. VPF/VEGF-A mRNA levels in a human podocyte
cell line grown in the presence of various extracellular matri-
ces were quantitated by real-time polymerase chain reaction
(PCR) experiments. VPF/VEGF-A protein levels in the cul-
ture supernatant from the same conditions were measured by
enzyme-linked immunosorbent assay (ELISA). Promoter ac-
tivity of VPF/VEGF-A gene in these cells was performed by
transfecting full length (2.6 kb) VPF/VEGF-A promoter, which
is fused with luciferase reporter gene. Immunoprecipitation and
Western blot experiments were carried out in order to detect
the association of hypoxia-inducible factor-a (HIF-a) and p300
in podocyte cells.
Results. In this study, we provide preliminary evidence that
signaling through the extracellular matrix proteins and, in par-
ticular, laminin and its receptor a 3b 1 integrin may regulate
VPF/VEGF-A production in cultured podocytes in vitro. We
also present data that increased activity of the transcription fac-
tor HIF-as in podocyte is not related to hypoxia and may lead
to up-regulation of VPF/VEGF-A transcription. The classical
type protein kinase C (PKC) may be a potential intermediate
signaling molecule in this event.
Conclusion. These data suggest a novel nonhypoxic regu-
lation of VPF/VEGF-A production in the glomerulus of the
kidney during physiologic states. These observations may form
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the basis of more elaborate studies that will finally provide
the detailed signaling pathway for VPF/VEGF-A synthesis in
podocytes and will help our understanding of the pathogenesis
of various VPF/VEGF-A–related diseases in the glomerulus of
the kidney.
Podocyte is a highly differentiated, polarized epithelial
cell that plays an important role in the physiology and
pathophysiology of the kidney glomerulus [1]. The basal
cell membrane of podocyte gives rise to long primary
processes called foot processes or pedicles. The pedicles
of neighboring podocytes regularly interdigitate, creat-
ing the filtration slits of a constant width of ∼30 to 40 nm
that are mainly responsible for the size selectivity of the
glomerulus filter [1]. An intact glomerular filtration bar-
rier is an essential part of a functional kidney. Any fail-
ure of this complex filtration system leads to proteinuria,
which is not only a prognostic clinical parameter but also
an important causative factor for progressive loss of renal
function [2–4]. A rapid and reversible retraction and flat-
tening of the foot processes occur due to the detachment
of podocyte foot processes from the glomerular base-
ment membranes (GBM) during proteinuria indicating
podocyte basement membrane adhesion to be of critical
relevance for a functional filter [2]. The molecules that are
considered to be important for podocyte-basement mem-
brane adhesion are the podocyte membrane receptors
(e.g., integrins [5] and dystroglycans [6]) and matrix pro-
teins like collagen IV [7], laminin, entacin, agrin, and per-
lecan [8]. Among the integrins, it is the a3b 1 that is highly
expressed in glomerular podocytes in a polarized pattern
along the GBM [9, 10]. It binds to collagen, fibronectin,
laminin, and entactin/nidogen, present in GBM [11, 12].
In fact, mice deficient in one of the laminin chains that
signals through a3b 1 integrin have been found to have im-
paired glomerular development [13]. Ligand binding to
a3b 1 integrin induces clustering of integrins to form focal
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adhesions and recruitment of intracellular cytoskeletal
proteins. It also leads to intracellular signaling for var-
ious other physiologic responses. Podocytes deficient in
a3b 1 integrin appear unable to assemble mature foot pro-
cesses, and cytoplasmic projections from the podocyte
body are flattened against the GBM [14]. GBM is also
found to be fragmented, and along much of its length,
a failure of fusion of the epithelial- and endothelial-
derived components has been detected [14]. The for-
mation of immature capillaries within glomeruli due to
the a3b 1 integrin–deficient podocyte also suggests a dy-
namic process during glomerulogenesis where migration
of podocytes around the in-growing capillaries, mediated
by a3b 1 integrin, plays an important role in stimulat-
ing capillary branching and maturation of the basement
membrane. Therefore, this may play an important role
as receptors, transducing signals on contact with the ex-
tracellular matrix (ECM), generate specific biologic re-
sponses that influence the behavior of both podocytes
and endothelial cells within the glomerulus. Until now
the detailed molecular mechanisms of the glomerular fil-
tration process were not completely understood, but it
is believed that vascular permeability factor/vascular en-
dothelial growth factor (VPF/VEGFA) has a distinct role
in this context [15, 16].
VPF/VEGF-A is a multifunctional cytokine with im-
portant roles in both vasculogenesis and angiogenesis
[17–23]. During glomerular development, the podocytes
express VPF/VEGF-A whereas its receptors, fetal liver
kinase-1 (flk-1) and fms-like tyrosine kinase 1 (flt-1),
are found in the endothelial cells [24]. In the mature
glomeruli, VPF/VEGF-A is also expressed suggesting it
plays a role in maintaining the filtration barrier either
through survival, proliferation, and/or differentiation
cues to the adjacent specialized endothelia. Very recent
evidence also suggests that VPF/VEGF-A secreted from
podocytes may act as an autocrine factor on calcium
homeostasis and cell survival [25].
Heterozygous mice at the age of 21/2 weeks with
podocyte specific knockout for VPF/VEGF-A shows
endotheliosis and “bloodless glomeruli” that progress
to nephrotic syndrome. The end-stage kidney failure
is also observed in the same heterozygous mice at 9
to 12 weeks. The podocyte-specific homozygous die at
birth or within 18 hours of birth with hydrops, kid-
ney failure, and grossly abnormal glomeruli that lack
mature endothelial cells [26]. Additionally, recent data
from our laboratory suggest that the proteinuria noted
in patients with preclampsia may be due to an excess
of circulating soluble VPF/VEGF-A receptor-1 (sFlt-1)
[27].
Moreover, a significant percentage of patients being
treated with VPF/VEGF-A signaling inhibitors in clinical
cancer trials have been found to have hypertension and
proteinuria [28].
Taken together these data suggest that constitutive ex-
pression of VPF/VEGF-A in the glomerular podocytes
maintains glomerular endothelial health and provides
a barrier against proteinuria during glomerular health.
During diseased states such as experimental glomeru-
lonephritis and thrombotic microangiopathy of the rat,
VPF/VEGF-A is involved in glomerular capillary repair
and healing [29, 30]. Impaired angiogenesis has also been
found in the remnant kidney model and correlates with
its progression. Kang et al [31] showed that VPF/VEGF-
A treatment reduces fibrosis and stabilizes renal function
in the remnant kidney model. There are close relation-
ships among VPF/VEGF-A, nitric oxide, endothelin-1,
and angiotensin II expression. Interestingly, all of them
are involved in a mechanism to regulate glomerular cir-
culation. Also of note, Eremina et al [26] again showed
that overexpression of the VPF/VEGF-A isoform in
podocytes causes end-stage renal failure due to a col-
lapsing glomerulopathy, which is the pathologic lesion
seen in HIV-associated nephropathy [26]. This illustrates
a tightly regulated signaling event that controls the ex-
pression of VPF/VEGF-A in podocytes and illustrates
the need for further molecular and genetic based studies
to elucidate the specific, responsible event.
VPF/VEGF-A production is generally regulated
by local oxygen concentration. Hypoxia stimulates
VPF/VEGF-A production by increasing the VPF/VEGF-
A gene transcription [32] and the stability of its mRNA
[33]. The increase in transcription occurs through the
binding of the transcription factor hypoxia-inducible fac-
tor (HIF) to the cis elements in the VPF/VEGF-A
promoter [34]. In normoxia, HIF-a subunits are rapidly
degraded by the ubiquitin-proteasome pathway, such that
the steady-state levels are low and the transcriptional
complex cannot form. It was found that the tumor sup-
pressor protein, von Hippel-Lindau gene product (VHL)
has a role in this degradation process. The multipro-
tein complex VHL, elongin b, c, cul-2 has structural ho-
mology with E3 type ubiquitin-ligase complex and can
indeed ubiquitinate the target protein [35, 36]. In high
oxygen concentration HIF-1a is hydroxylated at the pro-
line residues of its oxygen dependent degradation do-
main. This posttranslational modification of HIF-1a is
necessary for its recognition by VHL [37, 38]. However,
stabilization of HIF-1a protein levels per se was not suf-
ficient for the transcriptional activation of VPF/VEGF-
A. Recent evidence suggests that, in oxygenated cells,
HIF-1a is also hydroxylated at an asparagine residue at
the COOH-terminal transactivation domain (CAD). As
a result, the HIF-1 complex cannot bind to the adaptor
protein p300 to execute its transcriptional activity un-
der normoxic conditions [39–41]. Cellular oxygen con-
centration is not the only regulator of VPF/VEGF-A
synthesis. Some cancer cells can produce high levels of
VPF/VEGF-A even in normoxic condition. Clear cell
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renal carcinoma (RCC) like 786-0, pancreatic carcinoma
cell line, ASPC-1, fibrocarcoma cell line, HT1080, ovarian
cancer cells, etc., produce elevated levels of VPF/VEGF-
A, which are not dependent on hypoxia. In these cells,
either oncogenes or growth factors and their receptors
induce VPF/VEGF-A synthesis [42–45].
VPF/VEGF-A is expressed in the mature podocytes,
and its probable function is to maintain the proper filtra-
tion barrier in the glomerulus. As glomerulus is not in the
hypoxic region in the kidney, the presence of other stim-
ulatory signals is eminent. In this study, we provide pre-
liminary evidence that ECM/podocyte interaction may be
important for VPF/VEGF-A up-regulation in podocytes
in vitro. The a3b 1 integrin, upon interaction with laminin
in the GBM, may induce a signaling cascade that increases
the association of HIF and p300 in podocytes and, hence,
the transcriptional activity of VPF/VEGFA promoter.
METHODS
Stable podocyte cell line
A stable cell line of T-SV40 immortalized human
glomerular visceral epithelial cells has been used to un-
derstand the signaling events that regulate the expression
of VPF/VEGF-A in podocytes [46]. These transformed
cells retain numerous specific determinants of visceral
epithelial cells. Morphologically these cells show a
cobblestone-like appearance similar to parental cells,
though they tend to be smaller and grow more densely.
The immunologic characteristics of the transformed cells
fully correspond with those of parental cells and keep
the parental phenotype over successive passages. The
presence of cytokeratin, a marker for epithelial dif-
ferentiation, was identified in both the primary cells
and the transformed cells. Two other differentiation
markers PHM5, a podocyte specific surface protein and
CALLA, a podocyte membrane protein, were again
shown to express in this transformed cell. In addition, this
transformed cell also expresses WT1, another podocyte
specific marker (our unpublished data). The major inte-
grins expressed in these podocytes are a3b 1 integrins that
are similar to expression in the podocytes of the adult kid-
ney [47]. Like parental cells, this transformed cell has the
ability to synthesize fibrinolytic-related compounds with
a predominant secretion of free urinary plasminogen ac-
tivator (u-PA) and to a lesser extent of a plasminogen-
activator inhibitor (PAI-1)-tissue plasminogen activator
(t-PA) complex. The transformed cells also possess atrial
natriuretic factor (ANF) receptors linked to guanylate cy-
clase confirming its podocyte specificity. The phenotype
and differentiation characteristic of transformed cells are
same when cultured on matrix proteins although the
transformed cells displayed weaker binding to the matrix
compare to the parental cells [46, 47]. Cells were grown
on plastic or human ECM extracted from the placenta
(BD Biosciences, Bedford, MA, USA) or type IV colla-
gen (BD Biosciences) or laminin (BD Biosciences).
RNA preparation and real-time polymerase chain
reaction (PCR)
After washing twice with ice-cold phosphate-buffered
saline (PBS), podocytes were lysed using lysis buffer
from the RNeasy Mini Kit (Qiagen, Valencia, CA, USA).
The total RNA was extracted according to the RNeasy
Mini Kit protocol. We used the Taqman real-time PCR
method. The sequence for forward, reverse, and Taqman
middle primers for human VPF/VEGF-A and for human
36B4 (housekeeping gene) were taken from the PubMed
gene bank and synthesized (Integrated DNA Technol-
ogy, Coralville, IA, USA). VPF/VEGF-A forward 5′-
TAC CTC CAC CAT GCC AAGTG-3′; VPF/VEGF-A
reverse 5′-GAT GAT TCT GCC CTC CTC CTT-3′;
VPF/VEGF-A middle primer 5′-TCC CAG GCT GCA
CCC ATG GC -3′; 36B4 forward 5′-ATG CAG CAG
ATC CGC ATG T-3′; 36B4 reverse 5′-TCA TGG TGT
TCT TGC CCA TCA-3′; and 36B4 middle primer 5′-CAC
CAC AGC CTT CCC GCG AA-3′. Each real time PCR
reaction was performed using 0.5 lg total RNA, 25 lL
reverse transcription (RT)-PCR Master Mix (Applied
Biosystems, Foster City, CA, USA), 1.25 lL RNase in-
hibitor (Applied Biosystems), 50 nmol/L forward primer,
50 nmol/L reverse primer, and 100 nmol/L middle primer.
For reverse transcription, a 30-minute period at 48◦C was
run before inactivating the reverse transcriptase at 95◦C
for 10 minutes. Forty cycles at 95◦C for 15 seconds and
60◦C for 1 minute were performed with an ABI Prism
7700 Sequence Detector (Applied Biosystems). All ex-
periments were carried out three times; and, from each of
the three, triplicate readings were taken and the average
was calculated. The relative RNA amount was calculated
as follows:  = CT (VPF/VEGF-A sample) − CT (36B4
sample),  =  (transfected sample) −  (empty vec-
tor sample). Relative RNA amount in comparison to the
control = 2−. Average and standard deviation from
three experiments were calculated.
Transfection and luciferase assay
Human VPF/VEGF-A promoter (2.6 kb long full
length) was cloned into pGL3basic vector (Promega,
Madison, WI, USA) to study the VPF/VEGF-A pro-
moter activity using the firefly luciferase as a reporter
gene [45]. Podocytes were plated for transfection in a 60
mm tissue culture dish in such a way that cell conflu-
ency was 85% to 95% for all experiments. Plasmids were
transiently transfected with the Effectene Transfection
Kit (Qiagen) according to the manufacturer’s protocol.
Briefly, 1.0 lg of the VPF/VEGF-A promoter-luciferase
construct was re-suspended in EC buffer (150 lL), and
8.0 lL of Enhancer was added and incubated at room tem-
perature for 5 minutes. Effectene (25 lL) was then added,
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and the whole mixture was incubated for another 10 min-
utes. Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal bovine serum (FBS) (1 mL) was added to the
DNA mixtures and then added drop wise to the plate.
Thirty hours after transfection cells were washed with
PBS, lysed with reporter lysis buffer (Promega) at room
temperature for 15 minutes, and followed by luciferase
assay. Luciferase activity was measured with a lumi-
nometer (MicroLumat LB96P) (Berthold Technologies,
Germany) using the luciferase assay kit (Promega). Pro-
tein concentration of each lysate was measured to nor-
malize the luciferase reading. Triplicate readings were
taken for each experiment and standard deviations were
calculated.
Nuclear extract preparation
Podocyte suspension was incubated in a hypotonic
buffer [10 mmol/L HEPES (pH 7.8), 10 mmol/L KCl,
2 mmol/L MgCl2, 0.1 mmol/L ethylenediaminetetraacetic
acid (EDTA), 10 lg/mL aprotinin, 3 mmol/L dithiothre-
itol (DTT), and 0.2 mmol/L phenylmethylsulfonylfloride
(PMSF)] for 15 minutes in ice. Nonionic detergent IGE-
PAL (Sigma Chemical Co., St. Louis, MO, USA) (10%)
was then added to the cell suspension and mixed vig-
orously. Thereafter, the whole mixture was centrifuged
at 14,000 rpm in an Eppendorf centrifuge for 5 minutes.
The pellets were again suspended in a hypertonic buffer
solution [50 mmol/L HEPES (pH 7.8), 50 mmol/L KCl,
300 mmol/L NaCl, 0.1 mmol/L EDTA, 10 lg/mL apro-
tinin, 3 mmol/L DTT, and 0.2 mmol/L PMSF] and mixed
on a rotating rack for 25 minutes at 4◦C. Finally, the sam-
ple was centrifuged at 14,000 rpm for 10 minutes, and the
supernatant was collected as nuclear extract.
Immunoprecipitation and Western blot analysis
Immunoprecipitation was performed in 0.2 to 0.5 mg
of cellular protein from nuclear or whole cell extracts
with antibodies (1 lg) directed against HIF-2a, HIF-1a,
and p300, and pulled down by protein A agarose beads
(Pfizer-Pharmacia, New York, NY, USA). For immun-
odetection antibodies against HIF-2a, HIF-1a (Novus
Biological, Littleton, CO, USA) and p300 (Upstate, Lake
Placid, NY, USA) were used.
Enzyme-linked immunosorbent assay (ELISA)
VPF/VEGF-A was measured in the cell culture su-
pernatant using a commercial ELISA kit that measures
all the known isoforms of VEGF-A as previously de-
scribed [27]. This ELISA measures free VPF/VEGF-A
concentrations.
Cell adhesion assay
A 96-well microtiter plate was incubated with laminin
at 37◦C for 1 hour and then blocked with PBS contain-
ing 1% bovine serum albumin (BSA) for another hour
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Fig. 1. Vascular permeability factor/vascular endothelial growth factor
(VPF/VEGF-A) mRNA level in podocytes in the presence of different
matrices. Immortalized glomerular podocytes were grown on plastic,
human extracellular matrix (ECM), type IV collagen, or on laminin for
48 hours. Real-time polymerase chain reaction (PCR) was performed
using primers specific for VPF/VEGF-A with the total RNA isolated
from the podocytes cultured on these different matrices. The data rep-
resented here are the mean of three independent results.
at the same temperature. Podocytes were trypsinized and
suspended in serum-free DMEM at a density of 3× 105
cells/mL; then 0.1 mL of the cell suspension was incubated
with either antibodies (1:100 dilution, stock concentra-
tion 1 mg/mL) against integrin a3 (Chemicon Interna-
tional, Temecula, CA, USA) and b 1 (BD Pharmingen,
San Diego, CA, USA) or with control mouse IgG for 30
minutes. The cell suspensions were then added to each
well of the 96-well plate followed by incubation at 37◦C
for 3 hours. The attached cells were fixed and stained with
a 0.4% crystal violet in methanol (wt/vol) for 30 minutes.
After washing with distilled water, the stained cells were
monitored under microscope and photographed.
Protein kinase C (PKC) inhibitor assay
Podocytes were incubated with different concentra-
tions (7 nmol/L to 60 nmol/L) of a specific PKC inhibitor,
GO¨ 6983 (CalBiochem, San Diego, CA, USA). After
overnight incubation, nuclear extracts were collected
from the cells. Immunoprecipitation reaction with the
p300 antibody followed by western blot with either the
HIF-1a antibody or the p300 antibody was performed.
RESULTS
Laminin increases the total VPF/VEGF-A mRNA
and protein expression in podocytes
Stable podocytes are cultured in a 60 mm tissue culture
dish previously coated with either kidney-specific ECM,
laminin, or collagen IV. Total mRNA was collected from
the confluent cell culture, and real-time PCR was per-
formed with primers specific for VPF/VEGF-A. mRNA
level of 36B4 was also measured as an internal control in
order to normalize the result. The VPF/VEGF-A mRNA
level goes up in the presence of ECM and in the pres-
ence of laminin alone but not in the presence of colla-
gen IV (Fig. 1). This result suggests that the ECM, and
particularly the laminin present in the GBM, have the
ability to increase the VPF/VEGF-A mRNA level in the
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Fig. 2. Vascular permeability factor/vascular endothelial growth factor
(VPF/VEGF-A) protein level in podocytes in the presence of different
matrices. Sandwich enzyme-linked immunosorbent assay (ELISA) was
performed using specific antibodies targeting VPF/VEGF-A using the
conditioned media collected from the podocytes cultured on different
matrices. The data presented are the mean of two independent experi-
ments.
absence of hypoxia. The importance of ECM, especially
laminin for VPF/VEGF-A expression in podocytes, was
also confirmed by ELISA assay, where we found that the
protein levels of VPF/VEGF-A were significantly ele-
vated in the conditioned media for podocytes cultured
on ECM and laminin (Fig. 2).
The integrin a3b1 is important for the regulation
of VPF/VEGF-A synthesis in podocytes
Since laminin binds to integrins, we then tested to see if
this up-regulation of VPF/VEGF-A synthesis by laminin
is mediated through integrin a3b 1. Podocytes (5 × 105
cells) were incubated with antibodies against a3 anti-
body (Chemicon International, catalogue number MAB
2056) and b 1 (BD Pharmingen) at 37◦C for 30 minutes
in suspension, and the whole suspension was plated in
60 mm tissue culture dish previously coated with ei-
ther kidney-specific ECM or laminin for 48 hours. Cells
were also incubated with normal mouse IgG as a control.
Total mRNA was collected from confluent cell culture,
and real-time PCR was performed with primers spe-
cific for VPF/VEGF-A. Antibody treatment inhibits the
up-regulation of VPF/VEGF-A mRNA in ECM com-
pared to the control; and, more significantly on laminin
(Fig. 3A). This result demonstrates the importance of
laminin in VPF/VEGF-A up-regulation in podocytes
and suggests that the signaling event responsible of
VPF/VEGF-A synthesis in the podocytes may originate
due to the interaction of ECM and, in particular, laminin
with integrin a3b 1. Figure 3B represents a control adhe-
sion experiment where we showed that the integrin a3
and b 1 antibodies indeed could block the association be-
tween laminin and a3b 1 integrin of podocytes.
Promoter activity of VPF/VEGF-A gene increases
in the presence of ECM
VPF/VEGF-A promoter construct (2.6 kb) fused with
a luciferase reporter gene was transfected to a stable
podocyte cell line cultured in the presence or absence
of ECM. After 30 hours of transfection, total luciferase
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Fig. 3. (A) Vascular permeability factor/vascular endothelial growth
factor (VPF/VEGF-A) mRNA level after incubating the podocytes
with antibodies against a3 and b1. Real-time polymerase chain reaction
(PCR) was performed using primers specific for VPF/VEGF-A with
the total RNA isolated from the podocytes incubated with antibodies
against a3 and b 1 and on different matrices. The data represented here
are the mean of three independent results. (B) Adhesion of podocytes
to laminin in the presence of antibodies against a3 and b 1. Adhesion
experiment to laminin was performed with podocytes in the presence of
antibodies against integrin a3 and b 1 or with mouse normal IgG which
served as a control.
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Fig. 4. Vascular permeability factor/vascular endothelial growth factor
(VPF/VEGF-A) promoter activity in podocytes in the presence of dif-
ferent matrices. Plasmid DNA containing the full-length VPF/VEGF-A
promoter (2.6 kb) fused with luciferase reporter gene was transiently
transfected in podocytes cultured on different matrices. Total luciferase
activities in the cells were measured by a chemiluminescent reader. The
data represented here are the average of three independent results.
activity, which is proportional to the VPF/VEGF-A pro-
moter activity, was assayed. An increase in promoter ac-
tivity in the presence of ECM suggests that the increase
in transcriptional activity of VPF/VEGF-A promoter ac-
tivity in the presence of ECM is one of the major reasons
for VPF/VEGF-A synthesis in the podocytes (Fig. 4).
HIF-1a and HIF-2a proteins are expressed in podocytes
and remain unchanged when cultured in the presence
of ECM
Western blot experiments were performed with the nu-
clear extracts of the podocytes cultured in the presence
or absence of ECM. The specific monoclonal antibodies
were used against HIF-1a and HIF-2a proteins (Novus
Biological). These experiments (Fig. 5) suggested that
both HIF-1a and HIF-2a proteins are not degraded in
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Fig. 5. Hypoxia-inducible factor (HIF)-1a and HIF-2a protein level
is unchanged in podocytes cultured on extracellular matrices (ECMs).
Western blots were performed with the nuclear extract of podocytes
grown in the presence or absence of ECM. Antibodies against HIF-1a
and HIF-2a protein were used for this purpose.
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Fig. 6. Association between hypoxia-inducible factor (HIF) and p300
increases in podocytes in the presence of extracellular matrix (ECM)
and laminin. Nuclear extracts were prepared from podocytes in the
presence or absence of ECM. (A) Immunoprecipitation of the nuclear
extracts with anti p300 antibody followed by Western blot with anti-
HIF-1a antibody. (B) Immunoprecipitation experiment with anti-p300
antibody followed by Western blot with anti-HIF-2a antibody. (C) Nu-
clear extracts were prepared from podocytes in the presence or absence
of laminin. Immunoprecipitation of the nuclear extracts with anti-p300
antibody followed by Western blot with anti-HIF-1a antibody.
podocytes under normoxic condition, but the synthesis of
these proteins do not increase in the presence of ECM.
The association between HIF-1a and HIF-2a with
adaptor protein p300 increases in the presence of ECMs
Nuclear extract was collected from the podocytes
cultured in the presence or absence of ECM.
Immunoprecipitation was performed in 0.2 mg of nuclear
extracts with antibodies (1 lg) against p300 and protein A
agarose beads, followed by immunodetection with anti-
bodies against HIF-1a and HIF-2a (Fig. 6A and B). An in-
crease in association between p300, HIF-1a, and HIF-2a
was observed when the podocytes were cultured on ECM.
This also explains why the transcription of VPF/VEGF-A
increases in the presence of ECM. The same increase in
association between HIF-1a and p300 was observed when
the cells were plated in the presence of laminin (Fig. 6C)
suggesting its involvement in VPF/VEGF-A synthesis in
podocytes.
PKC (classical type) acts as an intermediary signaling
molecule in this pathway
Recent evidences [48, 49] suggest that PKC can act
as a downstream signaling molecule for many integrin-
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Fig. 7. Classical protein kinase C (PKC) regulates the association be-
tween hypoxia-inducible factor (HIF) and p300 in podocytes. Nuclear
extracts were prepared from podocytes in the presence or absence of
laminin. Upper panel represents the immunoprecipitation of the nu-
clear extracts with ant- p300 antibody followed by Western blot with
anti-HIF-1a antibody. Lower panel represents the immunoprecipita-
tion experiment with anti-p300 antibody followed by Western blot with
the same antibody.
signaling events. In order to know whether PKCs are also
important for HIF-1a activation in podocytes, we used
specific PKC inhibitors GO¨ 6983 (CalBiochem) at differ-
ent doses in podocytes. The IC50 values of different PKC
isozymes for GO¨ 6983 are different and actually help de-
termine the involvement of a specific type of PKC in a sig-
naling pathway. The IC50 values are as follows: For PKC
a and b , it is 7 nmol/L; for PKC d, it is 10 nmol/L; and for
PKC f , it is 60 nmol/L. The nuclear extracts of podocytes
cultured on laminin were collected after treating them
at different concentrations of the inhibitor. Immunopre-
cipitation was carried out with antibodies against p300
followed by Western blot against HIF-1a antibody. A de-
crease in the association p300 and HIF-1a was observed
at 7 nmol/L dose suggesting the involvement of classical
PKCs (PKC a and PKC b in this pathway (Fig. 7).
DISCUSSION
We demonstrate in this paper that podocyte expression
of VPF/VEGF-A involves a nonhypoxia-mediated path-
way that is dependent on podocyte basement membrane
interaction. Podocyte basement membrane interaction
is important for maintaining the proper filtration bar-
rier of the glomerulus and glomerular epithelial and en-
dothelial health [50]. The major integrin that is expressed
in podocytes and interacts with the matrix proteins of
GBM is a3b 1 integrin [9, 10]. Interestingly, a1 integrin–
deficient podocytes appear to remain adherent to the
basement membrane along their entire length of contact
suggesting that it is not a simple adhesion receptor [14]. It
may thus play an important role as receptors transducing
signals on contact with the ECM generate specific bio-
logic responses. We hypothesized that GBM and specif-
ically laminin interacts with a3b 1 integrin and results in
an increased VPF/VEGF-A synthesis. The experimental
results discussed here suggested that the VPF/VEGF-
A mRNA and protein level were up-regulated in the
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stable podocyte cell line in the presence of ECM, specif-
ically when cultured on laminin—a major matrix protein
in GBM. More important, blocking of a3b 1 integrin sig-
naling by incubating the cells with anti-a3b 1 integrin anti-
bodies decreased the VPF/VEGF-A mRNA levels com-
pared to controls in the podocytes cultured on laminin.
All these results suggested the importance of a3b 1 inte-
grin signaling event after its interaction with matrix pro-
tein like laminin for the up-regulation of VPF/VEGF-A
mRNA. The result presented in Figure 4 for VPF/VEGF-
A promoter activity in podocytes cultured in the pres-
ence or absence of ECM suggested that an increase in
VPF/VEGFA promoter activity might be important due
to an increase in the total mRNA level. Finally, we pre-
sented evidences that prove that the interaction of the
matrix protein with integrins in podocytes increased the
association of the transcription factor HIF with its adap-
tor protein p300 and thus provided a mechanistic expla-
nation of the increase in VPF/VEGF-A transcriptional
activity. We also showed that the PKC, especially the clas-
sical types, was the intermediate signaling molecule in this
pathway. Therefore, in this study experiments were per-
formed to elucidate the stimulatory event and its down-
stream signaling pathways that regulate VPF/VEGF-A
synthesis in the podocyte. However, there are limitations
to this study. Since we used transformed podocytes, the re-
sults of this study will need to be confirmed using primary
human podocyte cultures. We did not study specific iso-
forms of laminin and other integrin family members that
are expressed in podocytes. Finally, in vivo studies to look
at expression of VPF/VEGF-A in specific laminin or inte-
grin knockout animals will need to be done before draw-
ing definite conclusions. Nevertheless, this study is among
the first to describe a nonhypoxic regulation of VPF/
VEGF-A production during physiologic states. It forms
the foundation for more in-depth research studies of
this detail-signaling event at the molecular level for
VPF/VEGF-A synthesis in podocytes in the future.
A thorough knowledge of the molecular pathways of
VPF/VEGF-A synthesis in the podocytes is important
to gain insight into VPF/VEGF-A related disease pro-
gression in glomerulus such as preclampsia, thrombotic
microangiopathies, and diabetic nephropathy and is also
an important step toward identification of the potential
therapeutic targets to circumvent these diseases.
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